Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

VivoSim Labs, Inc. - Common Stock (NQ:VIVS)

2.525 -0.225 (-8.18%)
Streaming Delayed Price Updated: 3:43 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about VivoSim Labs, Inc. - Common Stock

News headline image
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevance 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platforms 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Roadzen Inc. (NASDAQ: RDZN) Accelerates U.S. Expansion with Strategic Acquisition – Surges on Record Volume – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference
From VivoSim Labs, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.